

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/00, C07H 19/00, 21/00, C07K 1/00, 14/00, 17/00	A1	(11) International Publication Number: WO 96/35777 (43) International Publication Date: 14 November 1996 (14.11.96)
(21) International Application Number: PCT/US96/06569 (22) International Filing Date: 9 May 1996 (09.05.96) (30) Priority Data: 08/437,317 9 May 1995 (09.05.95) US (71) Applicant: FOX CHASE CANCER CENTER [US/US]; 7701 Burholme Avenue, Philadelphia, PA 19111 (US). (72) Inventors: KATZ, Richard, A.; 272 Ironwood Circle, Elkins Park, PA 19027 (US). SKALKA, Anna, Marie; 23 Bouvant Drive, Princeton, NJ 08540 (US). (74) Agents: HAGAN, Patrick, J. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19102 (US).		(81) Designated States: CA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: CHIMERIC ENZYME FOR PROMOTING TARGETED INTEGRATION OF FOREIGN DNA INTO A HOST GENOME		
(57) Abstract <p>The present invention provides novel chimeric genes and fusion proteins useful for facilitating site-specific integration of foreign DNA into a host genome. The chimeric enzymes of the invention comprise a DNA binding moiety fused to a retroviral integrase moiety, preferably at the precise N- or C-terminus. Nucleic acids encoding these fusion proteins can be incorporated into standard retroviral vectors, or can be provided as purified proteins. They are capable of exerting the activities of a wild-type retroviral integrase, including processing retroviral DNA termini, nicking double-stranded DNA and integrating a DNA molecule with processed retroviral termini into another DNA strand.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**CHIMERIC ENZYME FOR PROMOTING TARGETED
INTEGRATION OF FOREIGN DNA INTO A HOST GENOME**

Pursuant to 35 U.S.C. §202(c), it is hereby
acknowledged that the U.S. Government has certain
rights in the invention described herein, which was
made in part with funds from the National Institutes of
5 Health.

FIELD OF THE INVENTION

The present invention relates to genetic
modification of eucaryotic organisms. In particular,
10 this invention provides novel fusion proteins
comprising a target-specific DNA binding moiety and a
retroviral integrase moiety. The enzyme is useful for
facilitating target-specific integration of foreign DNA
into a host genome.

15

BACKGROUND OF THE INVENTION

The practical utility of genetic engineering
often depends on introducing inheritable genetic traits
into organisms. To achieve this goal, foreign DNA must
20 be stably integrated into the DNA of the host organism.
Stable integration of foreign DNA into host DNA is
often referred to as "transformation" of the host cell
(or genome of the cell).

Genetic transformation in higher eucaryotes
25 is often accomplished through the use of viral vectors
which rely on stable integration in the host genome as
part of their replicative cycle. Retroviruses are one
of the few animal viruses that depend upon integration
for replication. A number of retroviral vector systems
30 are currently available to mediate transformation of
animal genomes. Such systems utilize one or more
vectors, at least one of which contains the portion of
the retroviral genome responsible for integration of
the viral genome into the host genome.

- 2 -

Integration of retroviral DNA requires a virus-encoded enzyme, the integrase (IN), which is encoded by the viral *pol* gene and carried within the virus particle. (For a review of the retroviral enzymes, including integrase, see Katz & Skalka, Ann. Rev. Biochem. 63: 133-173, 1994). Integration also requires cis-acting sequences at the ends of linear viral DNA. Integration is site-specific with respect to the viral DNA (it occurs at the linear ends), but appears to be nearly random with respect to host DNA.

Biochemical and genetic experiments indicate that integration takes place through two steps. First, IN nicks the viral DNA two nucleotides from the 3' ends of each DNA strand (referred to as the "processing" reaction). This nicking exposes the highly conserved CA dinucleotides, usually located two nucleotides from the 3' end of each strand. The new 3'-OH ends of each viral DNA strand are then joined to the host DNA in a second reaction (referred to as the "joining" reaction). The joining reaction is believed to proceed by a direct attack mechanism whereby the 3'-OH ends of viral DNA strands attack host DNA phosphates that are staggered by 4-6 base pairs. The simplest model for IN function is one in which a single monomer is bound to each end of viral DNA and each monomer is capable of binding viral DNA and host DNA simultaneously.

Both processing and joining activities can be assayed *in vitro* using short synthetic DNA substrates that mimic the single ends of retroviral DNA (see Katz & Skalka, 1994, *supra*). Both reactions are thought to be catalyzed by a single active site, due to the chemical similarity of the two reactions and the general inability to biochemically separate the two activities by mutagenesis.

IN is the only viral gene product required for integration of viral DNA into a host genome. For this reason, IN may be used to advantage to facilitate

- 3 -

genetic transformation of eucaryotic cells. However, its utility is limited due to its lack of sequence specificity with respect to the host DNA. That is, IN-catalyzed integration can occur essentially at random in the genome, which could result in activation or deactivation of host genes essential for cellular function. Thus, it would be a significant advance in the art of genetic transformation to develop retroviral integrases capable of site-specifically catalyzing integration of foreign DNA into a pre-determined location in the host genome.

It is an object of the present invention to provide modified retroviral integrases capable of enhancing the integration reaction and catalyzing integration of foreign DNA at a selected target location in a host genome. It is further an object of the present invention to provide retroviral vectors that encode such modified integrases, and which also contain the foreign DNA to be inserted into the host genome.

SUMMARY OF THE INVENTION

The present invention provides novel chimeric genes and fusion proteins to enhance stable integration of foreign DNA into host DNA, and to promote site-specific integration at a selected location in a target DNA molecule. The compositions of the invention are particularly useful for enhancing integration of foreign DNA carried on retroviral vectors, which should be of wide utility as a research tool to study the organization of gene expression pathways, as well as for gene-based diagnostic and therapeutic purposes.

According to one aspect of the present invention, a chimeric enzyme is provided, which comprises a DNA binding moiety and an integrase moiety derivable from a retroelement. The enzyme is capable of binding a DNA molecule having a characteristic

- 4 -

determinant recognized by the DNA binding moiety, and the enzyme possesses at least one activity characteristic of a retroelement integrase. Characteristic retroelement integrase activities

5 include processing of retroelement DNA termini, nicking within double-stranded DNA, and integrating a DNA molecule having processed retroelement termini into another DNA molecule. In a preferred embodiment, the chimeric enzymes of the invention possess all three

10 activities and integrates the processed DNA molecule into a site that neighbors the binding site recognized by the DNA binding moiety.

In preferred embodiments of the invention, the chimeric enzyme described above is constructed so

15 that the DNA binding moiety is fused to the integrase moiety at either the amino- or carboxyl-terminus of the integrase moiety. Carboxyl-terminal fusion proteins are particularly preferred because their encoding DNAs can be incorporated into replication-competent

20 retroviral vectors.

According to another aspect of the present invention, a nucleic acid molecule is provided, which has a sequence that encodes the chimeric enzyme described above. The nucleic acid molecule comprises a

25 DNA binding moiety-encoding segment operably linked to an integrase-encoding segment derivable from a retroelement. The nucleic acid may be disposed within a vector, which may be a retroviral vector (either a replication competent vector or a "helper" virus), a

30 cloning vector or an expression vector. In a preferred embodiment, the nucleic acid is disposed within a retroviral vector. If the nucleic acid encodes a chimeric enzyme in which the DNA binding moiety is fused to the C-terminus of the integrase moiety, a

35 retroviral vector may be constructed. These retroviral vectors may also contain a foreign DNA to be inserted into a host genome.

- 5 -

The novel chimeric genes and fusion proteins of the present invention represent a significant advance in the art of stable integration of foreign genes into host genomes. Whereas current retroviral integrase systems are capable only of catalyzing random integration of foreign DNA at low efficiency, the modified integrases of the invention are capable of enhancing the integration reaction and catalyzing integration of foreign DNA at selected targets located in a host genome.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1. Figure 1A shows a schematic representation of avian sarcoma virus (ASV) IN protein and various derivatives. The wild type IN protein, 286 amino acids in length, is depicted. The highly conserved amino acid residues are represented with the single letter code. Their position numbers and the domains that they define are also indicated. The putative catalytic residues are in bold. The filled boxes indicate the LexA repressor DNA binding domain (87 amino acids). The numbering of the various derivatives reflects the amino acids that are retained. The dashed vertical lines indicate the first four amino acids of IN that are retained as a "leader" or "spacer" in the majority of deletion and fusion proteins. The hatched region in LIN 39-207 indicates the presence of two heterologous amino acids at the C-terminus. Figure 1B shows the *lexA* operator sequence (Sequence I.D. No. 1) used as a target for experiments shown in Figures 3 and 4. Restriction sites for cloning into pBR322 are shown. The operator core sequences are shown in bold. The vertical lines indicate axis of dyad symmetry for each operator. Boxed region indicates the spacer between the two operators.

- 6 -

FIGURE 2. In vitro processing assay for IN and IN derivatives. Fig. 2A: wildtype IN, IN 18-286, L-IN 39-286, L-IN 52-286. Fig. 2B: IN 39-207, L-IN 39-207. Time course in indicated, NP indicates a control incubation without protein. Reaction products were fractionated on polyacrylamide-urea sequencing gels. "S" indicates labeled substrate strand from the duplex substrate that mimics the retroviral DNA end (see diagrams in lower parts of the figures, asterisk indicates ^{32}P label). ASV IN nicks the substrate between the A and T (as indicated by arrow in diagram Fig. 2A), releasing the TT dinucleotide. This produces a strand two nucleotides shorter than the substrate (denote "-2" band). The "-3" nicking (Fig. 2B) represents a non-specific activity which is prominent when using the preferred Mn^{++} ion as a co-factor; the catalytic domain fragment retains this "-3" activity.

FIGURE 3. Detection of in vitro integration events using a PCR-based assay. Labeled PCR products were fractionated on 7% polyacrylamide-urea sequencing gels. IN or IN fusions indicated above the lanes were incubated with the target plasmid containing the *lexA* operator segment depicted in Figure 1B. The bands corresponding to integration sites within the *lexA* operators were determined by using the indicated size markers (indicated in base pairs) as well as a ten-base ladder (not shown). The estimated borders of this region are indicated on the left. Arrows indicate bands corresponding to enhanced integration sites associated with N-LIN and C-LIN proteins.

FIGURE 4. Detection of in vitro integration events using a PCR-based assay. Proteins used in each assay are shown above. A control reaction was incubated without IN (lane 1, -IN). Symbols are as described in Figure 3.

- 7 -

FIGURE 5. Nicking (double strand break) assay for ASV IN and derivatives. Supercoiled substrate (form I, FI) was used in Figures 5A and 5B. Linear substrate was used in Figure 5C. Proteins used for reactions are indicated above lanes. Fig. 5A: plasmid (pNDE-1), a pBR322 derivative lacking *lexA* operators was used as a substrate. DNA forms (F) I, II and III are indicated. Marker DNA sizes are indicated in base pairs. Lane 1, marked CON, indicates that the reaction was incubated in the absence of IN. Fig. 5B: The plasmid (pBRBSLexAOP) was used as a substrate. This plasmid contains several tandem *lexA* operators. The F II band in the starting material (CON, Lane 1) may also contain supercoil dimer and a double strand break would produce a linear dimer [denoted F III (D?)] Fig. 5C: As in A and B, except that a *Pst*I I-linearized version of the pBRBSLexAOP plasmid was used as a substrate. Markers for linearization at the *lexA* operator region were generated by cleavage with *Pst*I and *Xho*I.

FIGURE 6. Strategy for construction of an ASV genome encoding C-LIN. Top portion is a diagram of the *env-pol* overlap region of ASV. A small peptide of 37 amino acids (stippled region) is normally removed by the viral protease (PR) from the C-terminus of IN after assembly. The *env* 3'-splice site (ss) is indicated. Middle portion of the figure shows pLD6IS1, in which a stop codon has been introduced that corresponds to the proteolytic cleavage site and a noncoding spacer (nc) has been introduced between *pol* and *env*. Using pLD6IS1 as an intermediate, pLD6 C-LIN was constructed by inserting a PCR-generated LexA DBD coding fragment (hatched) between existing *Ban* II and *Afl* II sites. In the bottom portion of the figure, the two PCR primers are shown, along with amino acids encoded at the IN-LexA DBD junction (vertical dashed line) (amino acid

- 8 -

sequence is Sequence I.D. No. 2, nucleotide sequence is Sequence I.D. No. 3) and at the new C-terminus of the C-LIN fusion (amino acid sequence is Sequence I.D. No. 4, nucleotide sequence from right to left is Sequence I.D. No. 5). Sequences in bold indicate LexA DBD coding sequences and corresponding amino acids.

FIGURE 7. Virus replication as measured by the reverse transcriptase assay after DNA transfection and infection of CEFs. Fig. 7A: CEF cell were transfected with a wild type viral DNA pLD6 (WT) and the C-LIN construct pLD6IS1 C-LIN (C-LIN). Virus production was monitored by the reverse transcriptase assay. Control cultures (CON) were not transfected. Fig. 7B: Supernatants collected on day 25 from Fig. 7A were normalized for RT activity and were applied to fresh CEF cultures. Control (CON) cultures were not infected. Virus production was monitored by the reverse transcriptase assay.

FIGURE 8. Western blot analysis of virus collected at day 30 post transfection. The viral clone used for the original transfection is indicated above each lane (see Figure 7). Virus particles were collected by pelleting and were applied to a 10% SDS-polyacrylamide protein gel. Western blots were probed with (Fig. 8A) anti-IN or (Fig. 8B) anti-LexA repressor protein rabbit polyclonal antibodies. The blots were developed with ¹²⁵I-labeled protein G. Molecular weight markers (in megadaltons) are indicated on the left side of each panel.

DETAILED DESCRIPTION OF THE INVENTION

It has been discovered in accordance with the present invention that the retroviral integrase (IN) can be fused with a heterologous DNA binding moiety (DB) to form a chimeric enzyme capable of enhancing

- 9 -

integration efficiency and facilitating site-specific integration of a foreign DNA molecule into a target DNA. These chimeric enzymes can be constructed as precise fusions of a DB to the N-terminus or C-terminus of retroviral IN. Alternatively, chimeric enzymes of the invention can be constructed by deleting a portion of the N-terminus of IN (specifically the ZF region, which in ASV is up to approximately 40 amino acids from the N-terminus) and thereafter fusing the DB to the N-terminal truncated IN.

As described in the background section, wildtype IN is capable of catalyzing all reactions necessary for integration of retroviral DNA. The precise C- and N-terminal fusion proteins of the present invention retain all activities ascribable to native IN, and are additionally capable of targeting a foreign gene to the target sequence recognized by the DNA binding moiety of the fusion protein and thereafter promoting the enhanced use of integration sites nearby the target DNA sequence. When optimized, these proteins may also enhance efficiency of the integration reaction, as well as facilitate targeted integration. Additionally, it has been discovered in accordance with the present invention that a retrovirus engineered to encode a chimeric enzyme comprising a C-terminal fusion of IN and a DNA binding moiety is competent to replicate within host cells.

N-terminal fusions of the DNA binding moiety to a location within the integrase ZF region are also capable of exerting most of the activities of native IN (i.e. processing viral DNA termini, concerted nicking of target DNA and joining of viral DNA to target DNA); however, integration catalyzed by these chimeric enzymes is not targeted to a neighboring site, as it is in the precise N- and C-terminal fusion proteins. These chimeric enzymes should find an additional utility as site-specific DNA cleaving agents, due to

- 10 -

their retention of the integrase concerted nicking activity in the vicinity of the DNA binding site.

The chimeric enzymes of the present invention are useful in a variety of forms for the purpose of facilitating stable integration of foreign DNA at a selected target position in a host chromosome or genome. In one embodiment, currently-available retroviral vectors can be modified such that they encode a DB/IN chimeric enzyme (instead of a native integrase). Such vectors may also encode the foreign DNA desired for insertion into a host genome, or they may be utilized as retroviral helper vectors to integrate foreign DNA provided on a separate gene transfer vehicle. Alternatively, purified enzymes of the invention may be provided as adjuvant with a foreign DNA of interest, to enhance targeted integration of the DNA. The chimeric enzymes of the invention are useful as research tools for studying the effect of insertional activation or disruption of genes in cultured cells or in animal model systems. More importantly, the chimeric enzymes of the invention can be used as diagnostic/therapeutic agents in a variety of currently available and developing gene transfer methodologies.

The detailed description set forth below describes preferred methods for making and using the chimeric enzymes of the present invention. Any molecular cloning or gene transfer techniques not specifically described are carried out by standard methods, for example as generally set forth in Sambrook et al., "DNA Cloning, A Laboratory Manual," Cold Spring Harbor Laboratories, 1989 (hereinafter Sambrook et al.); and Ausubel et al. (Editors), "Current Protocols in Molecular Biology," John Wiley & Sons, Inc., 1995 (hereinafter Ausubel et al.).

- 11 -

I. PREPARATION OF CHIMERIC ENZYMES COMPRISING A
DNA BINDING MOIETY AND AN INTEGRASE MOIETY

The chimeric enzymes of the present invention
5 comprise two components: an integrase (IN) domain and a
DNA binding (DB) domain. These domains may be arranged
as precise C- or N-terminal fusions with respect to the
integrase moiety, or may comprise N-terminal fusions
wherein a portion of the IN N-terminus has first been
10 deleted. In accordance with the present invention, it
has been discovered that the ZF domain of IN
(comprising approximately the first 40 amino acids of
the protein in ASV) is not essential to maintain the
activities of the IN moiety. The fusion proteins of
15 the invention are sometimes referred to herein as
"DB/IN" or as "N-DB/IN" or "C-DB/IN" to denote that the
DNA binding moiety is attached at the N-terminus or the
C-terminus of the IN moiety, respectively. Finally,
chimeric enzymes that comprise an N-terminal fusion in
20 which a portion of the IN moiety has been deleted are
sometimes referred to herein as "DB/IN" followed by a
pair of numbers, which refer to the amino acid residues
included in the IN moiety of the fusion protein (for
example, residues 18-286 of ASV IN fused to the LexA
25 DNA binding domain, as described in Example 1, is
referred to as LIN 18-286).

The DB/IN fusion proteins of the invention
are prepared by recombinant DNA methods, in which DNA
sequences encoding each domain are "operably linked"
30 together such that upon expression, a fusion protein
having the targeting and integrase functions described
above is produced. As used herein, the term "operably
linked" means that the DNA segments encoding the fusion
protein are assembled with respect to each other, and
35 with respect to an expression vector in which they are
inserted (including retroviral vectors), in such a
manner that a functional fusion protein is effectively
expressed. The selection of appropriate promoters and

- 12 -

other 5' and 3' regulatory regions, as well as the assembly of DNA segments to form an open reading frame, employs standard methodology well known to those skilled in the art.

5 Thus, preparing the chimeric enzymes of the invention involves selecting DNA sequences encoding each of the aforementioned components, operably linking the respective sequences together in an appropriate vector, and expressing the sequences to produce the
10 chimeric enzyme. Each of these steps is described below.

 It will be appreciated by persons skilled in the art that the DNA components assembled for expressing the chimeric enzymes of the present
15 invention can be prepared in a variety of ways, including DNA synthesis, cloning, mutagenesis, amplification, enzymatic digestion, and similar methods, all available in the standard literature. Additionally, certain of the components can be obtained
20 easily through commercial sources or by access to public repositories, such as the American Type Culture Collection. Alternatively, components that are not readily available, and/or for which sequence information is not available, can be isolated from
25 biological sources using standard hybridization methods and homologous probes that are available.

 Due to the high level of conservation among retroviruses, retrotransposons and other retroelements, DNA sequences encoding the integrase moiety of the
30 fusion proteins of the invention can be selected from any of these sources. As used herein, the term "retrovirus" refers to a class of viruses in which the genetic material is RNA, but which completes its replicative cycle by means of a DNA intermediate, which
35 becomes integrated into the genomic DNA of host cells (see Background section). The term "retrotransposon" refers to a class of mobile DNA elements that possess

- 13 -

long terminal repeats (LTRs, generally a few hundred base pairs in length), which replicate through RNA intermediates that are copied by reverse transcriptase (a retrotransposon may be thought of as a retrovirus for which an infectious extracellular form does not exist, or has not yet been discovered). The term "retroelement" refers collectively to retroviral DNA, retrotransposons and other transposable elements having the above-described characteristics. Retroelements encode at least one, and generally all, of the following three enzymes: reverse transcriptase (RT), protease (PR) and integrase (IN). Any retroelement that encodes an integrase may be utilized as a source for DNA sequences encoding the IN moiety of the invention. Such retroelements include, but are not limited to: (1) retroviruses such as human T-cell leukemia virus (HTLV) types I and II, bovine leukemia virus (BLV), simian retrovirus type I (SRV-I), mouse mammary tumor virus (MMTV), avian sarcoma virus (ASV), human immunodeficiency virus (HIV), human spuma (foamy) virus (HFV), visna lentivirus (VISNA), Moloney mouse leukemia virus (Mo-MLV), feline immunodeficiency virus (FIV) caprine arthritis-encephalitis virus (CAEV) equine infectious anemia virus (EIAV), human endogenous retrovirus (HERV) type C and type K, and hamster intercisternal particle (IAP-18); and (2) retrotransposons and other retroelements, such as Ty-1, Ty-3, Copia, Gypsy, 297, 17.6, and 412. For a review of eucaryotic and procaryotic retroelements, see, e.g., Doolittle et al., Quarterly Review of Biology 64: 1-30 (1989); Garfinkle Chapter 4 in The Retroviridae, Volume 1, J.A. Levy, Ed., Plenum Press, New York (1992) pages 107-158.

A variety of DNA binding proteins have been isolated and characterized in recent years. Any of these DNA binding proteins can serve as appropriate sources for the DNA binding moiety of DB/IN fusion

- 14 -

proteins. Moreover, as new DNA binding proteins are isolated and characterized, these may also been utilized to construct DB/IN proteins of the invention. For optimum practice of the present invention, it is
5 important to select DNA binding domains that recognize one or more specific characteristic determinants of a DNA molecule, rather than binding randomly to DNA. As used herein, the term "characteristic determinant" refers to one or more sequence or structural features
10 unique to a particular gene or other specified location on a DNA molecule. As will be appreciated by those skilled in the art, such characteristic determinants generally involve a specific primary DNA sequence, as well as positioning of one or more such sequences
15 relative to one another on a DNA double-helix, possible combined with other structural features of eucaryotic chromosomal DNA.

Chimeric enzymes comprising the LexA DNA binding domain are described in detail in Example 1.
20 These fusion proteins serve to demonstrate that integrase indeed can be constructed as a fusion protein with a DNA binding moiety to produce a chimeric enzyme that can facilitate site-specific integration of a foreign gene. However, the greater practical utility
25 of the invention is directed to eucaryotic host DNA since retroviral vectors are used in eucaryotic systems. Accordingly, DNA binding proteins targeted to eucaryotic genes are preferred for practice of the invention. Particularly preferred are eucaryotic
30 transcription factors that possess DNA binding domains, such as those that act in concert with RNA polymerase, as described by Burley, Current Opinion in Structural Biology 4: 3-11 (1994). These include, but are not limited to: TATA box binding proteins (TBP),
35 specifically TBP isoform 2; b/hlh/z factors, such as Max and USF; helix-turn-helix variants, such as the third repeat of c-Myb, the POU-specific domain Oct-1,

- 15 -

the homeodomain from LSI1/HNF1 and the fork head domain of HNF-3 γ ; the DNA binding domain of GATA-1; the nucleic acid binding domain of transcription factor IIS; and the 5 zinc-finger GLI DNA binding domain. Also particularly preferred are eucaryotic transcription factors such those that regulate differential gene expression in cellular growth, development and differentiation (see, e.g., D.S. Latchman, "Eukaryotic Transcription Factors," Academic Press, Inc., San Diego, 1991). These include, but are not limited to, NF κ B, KBF1 C/EBP and CRE binding proteins, and other transcription regulators encoded by genes such as *erbA*, *ets*, *fos*, *jun*, *myb*, *myc*, *rel* and *spi-1*.

As discussed above, DB/IN enzymes of the invention may be utilized as purified proteins or as DNA sequences encoding the protein, to be included on a retroviral vector and expressed *in situ* by cellular enzymes. Thus, either retroviral vectors or expression vector systems will be required to practice the invention.

Numerous retroviral vector systems are publicly or commercially available. These systems generally comprise vectors for carrying the foreign DNA of interest and a packaging or helper cell line which contains viral sequences encoding trans-acting proteins (although some vectors comprise all sequences necessary for replication competence). Several recently-developed retroviral vector systems are described by Boris-Lawrie & Temin, Curr. Op. Genet. Devel. 3: 102-109 (1993). Other are known in the art (see, e.g., Ausubel et al., Chapter 9.10, 9.11).

Retroviral vectors can be modified to substitute a DB/IN of the invention for the standard integrase gene carried on the vector, utilizing standard recombinant DNA techniques. Alternatively, the integrase gene carried on a retroviral vector may be modified by adding sequences encoding a DNA binding

- 16 -

moiety at the N- or C-terminus, or within the N-terminal ZF domain, in accordance with the description set forth above. These substitutions or modifications may be carried out on retroviral vectors destined to contain the foreign DNA of interest or, alternatively, on "helper" retroviral vectors in a gene transfer system in which the foreign DNA of interest is carried on a separate vector. Modification of a retroviral vector to comprise a DB/IN-encoding gene of the invention is described in greater detail in Example 1.

Retroviral vectors comprising DB/IN sequences are used according to standard methods to transfect eucaryotic cells (either cultured cells or cells within a living organism). The chimeric enzyme of the invention is then expressed within the transfected cells and is thus available to facilitate targeted integration of foreign genes carried on that same vector or a separate vector.

The chimeric enzymes of the invention may also be produced using other *in vitro* expression methods known in the art. For example, DNA sequences encoding the protein may be cloned into an appropriate *in vitro* transcription vector, such as pSP64 or pSP65, for *in vitro* transcription, followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocytes. *In vitro* transcription and translation systems are commercially available, e.g., from Promega Biotech, Madison, Wisconsin or BRL, Rockville, Maryland.

Alternatively, according to a preferred embodiment, the chimeric enzymes may be produced by expression in a suitable procaryotic or eucaryotic cellular system. For example, DB/IN sequences may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as *E. coli*, or into a baculovirus vector for expression in an insect cell. Such vectors comprise the regulatory elements necessary

- 17 -

for expression of the DNA in the bacterial or eucaryotic host cell, positioned in such a manner as to permit expression of the DNA in the host cell.

5 Production of a chimeric enzyme of the invention by expression in a procaryotic system is describe in greater detail in Example 1.

The protein produced by expression in a recombinant procaryotic or a eucaryotic system may be purified according to methods known in the art. In a
10 preferred embodiment, a commercially available expression/secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression/secretion
15 vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to one or more moieties of the recombinant protein. Such methods are
20 commonly used by skilled practitioners. Purification of a chimeric enzyme of the invention after expression in a procaryotic system is described in greater detail in Example 1.

25 **II. METHODS OF USING DB/IN ENZYMES,
AND SPECIFIC APPLICATIONS**

The methods of the invention generally involve combining host DNA (e.g., genomic DNA from higher eucaryotes) with foreign DNA in the presence of
30 a chimeric enzyme of the invention in such a manner as to enable the enzyme to catalyze the site-specific integration of the foreign DNA into a selected target site of the host DNA. The foreign DNA is carried within a retroviral vector, or is modified to provide
35 linear double-stranded segments that have terminal DNA sequences recognizable by the DB/IN enzyme. The enzyme thereafter supplies the necessary processing and joining catalytic functions for integration into the

- 18 -

pre-determined target site, and cellular repair enzymes (e.g., DNA polymerases and ligases) provide the requisite gap-filling and ligation functions to accomplish full integration.

5 The chimeric enzymes of the invention can be utilized for site-specific modification of host DNA either extracellularly or intracellularly. In the extracellular application, host DNA is removed from cells or otherwise purified, either as a total DNA
10 fraction or as intact chromosomes, and combined with the foreign DNA of interest and the chimeric enzymes (or gene encoding the enzyme) in a suitable biological buffer, along with any other biological reagents necessary for completing integration of the foreign DNA
15 into the host DNA. This *in vitro* utility of the chimeric enzymes of the invention should find broad application in preliminary research, in which the effect of targeted, stable insertion of a foreign DNA into a host gene or chromosome is being studied or
20 explored.

 In most applications of the invention, it is preferable to utilize the DB/IN chimeric enzymes *in situ*, i.e., within cells containing host DNA. To accomplish this, the chimeric enzyme is introduced into
25 cells by expression from a retrovirus helper or vector, or as protein or DNA. For a retroviral helper, a cell line is created that expresses all retroviral proteins, with the DB/IN replacing the native integrase. The retroviral vector is then introduced by transfection
30 into a cell of interest. Similarly, a replication-competent vector comprising C-terminal DB/IN fusions and the foreign DNA of interest, may be introduced into a cell line by transfection or by a variety of other methods known in the art for introducing DNA and/or
35 proteins into a cell. Such methods include, but are not limited to: (1) calcium phosphate co-precipitation; (2) DEAE-dextran treatment; (3) electroporation; (4)

- 19 -

biolistic delivery (i.e., bombardment of cells or tissues with DNA-coated microparticles); (5) microinjection; (6) "scrape-loading," as described by McNeil et al., J. Cell Biol. 98: 1556-1564 (1984); and
5 (7) liposome- or erythrocyte-mediated transfection. These and other currently-available methods may be utilized on cultured or non-cultured cells, excised tissues or within a living organism.

The chimeric enzymes of the present invention
10 will find their broadest utility as general enhancers of the integration reaction and as facilitators of targeted integration of foreign DNA into host DNA within cultured cells or within cells of a living organism. The enzymes will be useful as a research
15 tool to study the effect of insertional disruption or enhancement of one or more genes within the natural cellular environment. As a specific example, transcription factors, which are the subjects of intensive research, are known to regulate groups of
20 genes at different stages of development or at different times in a cell cycle. These genes are "turned on" or "turned off" at specific developmental stages or times, such regulation orchestrating the expression of genes under control of the transcription
25 factors. It is now known that these factors are open for activation by certain changes occurring in the chromosomal DNA which enable binding of DNA binding proteins that activate expression of the transcription factors. Since several of these DNA binding proteins
30 have already been isolated and characterized, their DNA binding domains can be utilized in construction of DB/IN proteins of the invention. Because the protein is directed to a binding domain which is only "open" at certain times, the chimeric enzyme may be used as a
35 probe to explore when, or at which developmental stages, a particular transcription factor is open for activation.

- 20 -

As another specific example, the DB/IN chimeric enzymes will be useful as a diagnostic and/or therapeutic tool, e.g., for disrupting genes known to have a detrimental effect. For instance, certain regulatory proteins are involved in cellular proliferation. For such proteins in which an activating DNA binding protein is known and has been characterized (for a list of examples, see Latchman, 1991, *supra*, at page 155), chimeric enzymes can be produced in accordance with the present invention to specifically disrupt expression of such genes by stable integration of a foreign DNA at the binding locus, thereby permanently inactivating the detrimental gene. In comparison, many gene- or RNA-inactivating strategies involve only transient measures, such as introduction of antisense molecules or ribozymes, and do not permanently inactivate a gene. In addition, as it becomes feasible to design DNA binding domains that bind to selected DNA recognition sequences or other characteristic determinants, DB/IN enzymes may be constructed that catalyze integration into a specific target site (e.g., at innocuous sites between expressed genes), to enable gene addition therapy without disrupting normal gene expression.

The use of the chimeric enzymes of the invention to disrupt or augment gene expression can first be explored in cultured cells, and thereafter can be utilized in living organisms. In this regard, the chimeric enzymes of the invention can be used to particular advantage for gene transfer in germline cells, such as bone marrow or stem cells from peripheral blood. These cells can be genetically manipulated *ex vivo* during the course of a normal autologous stem cell transplantation procedure.

The DB/IN enzymes of the present invention should be of substantial utility in facilitating site specific integration of foreign DNA molecules into host

- 21 -

DNA *in vitro*, in cultured cells, and in living animals. This is a significant advance in the art with respect to stable transformation of eucaryotic DNA by way of retroviral vectors, which heretofore were capable only of catalyzing random integration events.

The following example is provided to describe the invention in further detail. This example is intended to illustrate and not to limit the invention.

10

Example 1

In this example, we describe in detail chimeric IN proteins containing the lexA DNA binding domain (DBD) fused precisely at the N- or C-termini of ASV IN, or within the N-terminal ZF domain of ASV IN. These fusion proteins demonstrate great potential for enhancing targeted retroviral integration into host DNA.

15

MATERIALS AND METHODS

20

Construction and purification of LexA-IN fusion proteins. We constructed a set of six LexA-ASV IN fusions in which the LexA DBD replaced various portions of the N-terminus of IN or was fused directly to the N- or C-termini (Figure 1). The sequence encoding the LexA DNA binding domain was derived from the plasmid pRB451, kindly provided by R. Brent (the sequence is also publicly available from the GENE BANK-National Center for Biotechnology Information, Accession No. J01643-V00299-V00300; see also Horii et al., Cell 23: 689-697 1981). PCR primers were designed to amplify the region corresponding to the LexA DBD, codons 1-87. For N-LIN, EcoRI sites were engineered into both PCR primers such that the LexA DBD coding region could be inserted into the unique EcoRI site located at the 5'-end of the RSV IN reading frame in the expression vector pRC23IN (pRC23 is a commercially available expression vector; pRC23IN is described as

25

30

35

- 22 -

"pRC23-p32" by Terry et al., J. Virol. 62: 2358-2365, 1988). N-terminal deletion mutations in which residues 5-52 or 5-39 of RSV IN have been deleted were described elsewhere (Kulkosky et al., Virology 206: 448-456, 1995). These N-terminal deletions were assembled into pRC23IN. In the deletion constructs, the *EcoRI* site at the 5'-end of IN has been retained along with codons for the first four IN amino acids. The LexA DBD sequence, adapted with *EcoRI* site, was inserted at the unique *EcoRI* site in these two constructs, producing the construct LIN 39-286 and LIN 52-286 (Figure 1). A similar approach was used to construct LIN 39-207 from 39-207, which was described elsewhere (Kulkosky et al., 1995, *supra*).

The LIN 18-286 was constructed using a different strategy. The C-terminal border of the LexA DBD sequence is defined by an *XmnI* site, so an *XmnI* partial digest was performed on pRB451. The *PstI* site in the *amp* gene is common to pRC23IN and pRB451 and this was used to transfer a small cassette containing the *Tac* promoter from pRB451 along with the first 87 amino acids up to the *XmnI* site. This fragment was cloned into pRC23IN that had been cleaved with *BssHII*, repaired and cleaved with *PstI*. The *BssHII* site corresponds to codon 17 of IN. Ligation of the blunt *XmnI* site to the repaired *BssHII* site resulted in an in-frame fusion between the LexA DBD codon 87 and ASV IN codon 18. An analogous deletion (IN 18-286), missing IN codons 5-17, was constructed by cleaving pRC23IN with *BssHII* and *EcoRI* and inserting a small *EcoRI/BssHII* linker that reestablished only the first four codons.

The C-LIN (Figures 1 and 6) was constructed in a manner that was amenable for reassembly into the viral genome. The LexA DBD coding region was amplified from the plasmid pRB451. The PCR primers included a *BanII* site on the upstream side and an *AflIII* site on

- 23 -

the downstream side. The downstream PCR primer contained a stop codon which would terminate the LexA DBD after amino acid residue 87. The *Ban*II/*Afl*III-adapted LexA DBD fragment was inserted into pSP73ASV-IS1 (Bouck et al., *Molec. Cell. Biol.* 15: 2663-2671, 1995) which contains the C-terminus of integrase as well as an adapter that separates the IN coding region from the overlapping env reading frame. The adapter also contains a single nucleotide change that was selected *in vivo*, which restores regulated splicing at the neighboring env splice site.

The proteins diagrammed in Figure 1 were purified from *E.coli* as described previously (Kulkosky et al., 1995, *supra*), except for LIN 18-286, which was purified by an earlier method (Terry et al., 1988, *supra*). All proteins were soluble and behaved similarly to the wildtype ASV IN.

LexA operator DNA. For the DNA nicking experiments shown in Figure 5, a consensus *lexA* operator segment was present which was in a ca. 750bp *Bam*HI/*Sal*I fragment from the plasmid 1107 kindly provided by R. Brent, (Brent & Ptashne, *Cell* 43: 729-736, 1985). The operator region was transferred to pBR322 by replacing the *Bam*HI/*Sal*I fragment. This plasmid is denoted pBRBSLexAOP. The *lexA* operator had *Xho*I ends and was inserted into an *Xho*I site. When partial digests were carried out to confirm the presence of the 24 bp operator, we noted a ladder of five bands, consistent with the presence of four tandem operators. Sequence analysis confirmed the presence of multiple operators.

A second plasmid was constructed containing two tandem *lexA* operators. A synthetic 63mer oligonucleotide duplex was prepared containing: *Bam*HI and *Sal*I restriction site for cloning into pBR322, two consensus operators with upstream and downstream spacers and a spacer sequence between the two operators

- 24 -

derived from the natural *lexA* tandem operators (Figure 1). The resulting plasmid pBR711-2 was sequenced to confirm the presence of the operator segment.

Processing assay. LexA-IN fusions were
5 assayed for the ability to process viral DNA ends using a model substrate described by Katzman et al., J. Virol. 63: 5319-5327 (1989). Briefly, the substrate consists of a synthetic duplex of 18bp analogous to an end of linear viral DNA. Incubation with IN in the
10 presence of 3mM MnCl₂ results in specific nicking two nucleotides from the 3' end of one strand ("processing"). This reaction removes the TT dinucleotide to produce a recessed end and exposes the highly conserved CA dinucleotide, which becomes joined
15 to the host DNA. The 5'-end of the target strand is labeled and the product, which is two nucleotides shorter, is detected by electrophoresis on a denaturing gel.

Plasmid nicking assay. Assays for concerted
20 nicking were carried out as described by Terry et al., 1988, *supra*, with some modifications. The reaction mix contained 20mM Tris-HCl pH 7.4, 3mM MnCl₂, 100 ngs of supercoiled plasmid DNA or linear DNA, and 5 pmoles of IN or *lexA*-IN protein. Reactions were incubated for
25 0.5 to 2 hours and were loaded on a 1% agarose gel. We observed that de-proteinization did not affect the results, so this step was not included. The gels were stained with ethidium bromide and visualized under ultraviolet light.

Assay for integration into pBR322 targets containing *lexA* operators. Integration of the model viral DNA duplex into a heterologous target was measured using a PCR-based assay similar to that described by Pryciak et al., EMBO J. 11: 291-303
35 (1992). The target DNAs, pBR322 derivatives, contain the *lexA* operator region. To measure integration into a specific region, a "target" PCR primer was selected,

- 25 -

which was ca. 250bp from the *lexA* operator region. The "viral" primer was identical to the 16nt DNA strand to be joined to the target DNA. The length of the PCR product corresponds to the distance from the target primer site to the integration site. Integration assays contained approximately 0.2 pmoles of *Pst*I linearized plasmid target DNA, 35 pmoles of IN or IN-*lexA* fusion protein and 0.1 pmol of viral DNA ends (model substrate). The reaction mixture contained 20mM Tris-HCl and 5mM MgCl₂. The viral DNA substrate was a 18mer/16mer duplex with a recessed end. This corresponds to a processed viral DNA end, as described previously (Katzman et al., 1989, *supra*). The viral DNA substrate and IN were incubated on ice for 10 minutes and the targeted DNA and metal were then added. Reactions were carried out for 60 to 90 minutes at 37°C. The reaction mix was treated with Proteinase K (200µg/ml f.c.) and 0.5% SDS for one hour at 37°C. Carrier tRNA was added and nucleic acids were purified by phenol extraction and concentrated by ethanol precipitation. The target DNA, now containing inserted viral DNA ends, was resuspended in 100µl 200 mM Tris-HCl (pH 7), 1 mM EDTA. Recovery of target DNA was monitored by agarose gel electrophoresis. Samples (5 to 10µl) were removed for PCR analysis. Standard PCR conditions were 1 minute at 94°C, 1 minute at 37°C and 1 minute at 72°C, 30 cycles. The target PCR primer was ³²p end-labelled and viral PCR primer was unlabelled. Products were analyzed on 7% acrylamide-urea sequencing gels. Fragment sizes were determined using a ØX174HaeIII digest and a 10bp ladder (Bethesda Research Labs).

Transfections, virus replication assays and western blot analysis. Transfections of chicken embryo fibroblasts was carried out as described by Katz & Skalka, *Mol. Cell Biol.* 10: 696-704 (1990), using the DEAE-dextran method. Virus production was monitored

- 26 -

using a standard reverse transcriptase assay. For protein analysis, virus particles were pelleted from 10ml of culture supernatant and proteins were fractionated on SDS polyacrylamide gels. Western blots were carried out as described previously using rabbit polyclonal antibody directed against the LexA repressor protein and rabbit polyclonal antibody directed against bacterially-produced ASV IN ("p36") (Stewart & Vogt, J. Virol. 65: 6218-6231, 1991).

10

RESULTS

Construction of lexA repressor DBD-IN fusions proteins. The lexA repressor is composed of a DNA binding domain (DBD, residues 1-87) and a dimerization domain (residues 88-202). High affinity binding of the repressor to cognate operators requires dimerization. We designed several truncated and full length ASV IN proteins containing the LexA repressor DBD (Figure 1). Our initial premise was that the N- and C- termini of IN may be involved in recognition of host or viral DNA, and by replacing either terminus, we could determine whether a heterologous DNA binding domain could complement IN function. The isolated central domain of ASV IN retains a nonspecific endonuclease and a cleavage-ligation activity; therefore this domain must be capable of DNA binding independently of the N- and C-termini. The central domain of IN also contributes to dimerization and therefore could provide the dimerization function required for high affinity binding of the lexA DBD. We fused the lexA DBD to the N-terminus of ASV IN at residues 18, 39 and 52, which resulted in partial or complete removal of the ZF domain. In addition, we designed several analogous IN deletions which lacked the lexA DBD. The lexA DBD was also fused to the central domain, 39-207. Lastly we constructed two fusions in which the LexA DBD was present at either the N- or C-terminus (n-LIN and C-

- 27 -

LIN, respectively). All of the fusions shown in Figure 1 were soluble when expressed in *E. coli*. Two additional constructs were designed to produce protein in which the LexA DNA binding domain was either
5 tethered at the N-terminus through a spacer or fused near the C-terminus (not shown). Proteins produced from these clones could not be purified by standard methods and were not analyzed further (not shown).

Processing and endonuclease activities of
10 fusion proteins. The chimeric proteins and deletion mutants shown in Figure 1 were assayed for processing activity *in vitro* using standard model substrates (Figure 2). Wild type ASV IN is able to cleave the DNA specifically following the conserved CA dinucleotide as
15 indicated. Fusion of the LexA DBD to IN amino acid positions 18 or 39 resulted in retention of wildtype processing activity (IN 18-286, IN 39-286). Joining activity, manifested by insertion of the newly formed ends in other substrate molecules, could also be
20 detected on longer exposures of the gel (data not shown) and was similar to wildtype. Similar activities were noted with constructs IN 18-286 and IN 39-286, indicating that activity did not depend on the presence of the LexA DBD (data not shown for the IN 39-286
25 protein). Fusion of the LexA DBD at residue 52 (LIN 52-286), however, resulted in a dramatic reduction of processing activity. The non-fused version of 52-286 appeared to be unstable in *E. coli* and thus could not be assayed.

30 We previously observed that deletion of the C-terminus of IN (IN 1-207 construct) resulted in loss of processing activity, but retention of a Mn^{++} -dependent endonuclease activity which cleaves between the C and A ("-3" cut), as well as other sites
35 (Kulkosky et al., 1995, *supra*). The wildtype ASV IN also displayed the "-3" cutting activity (Figure 2). This activity is a property of ASV IN, as indicated by

- 28 -

specific inhibition by certain anti-ASV IN monoclonal antibodies. The IN 39-207 and IN 52-207 fragments retained this "-3" cutting activity (Figure 2, data not shown for IN 52-207). The central domain fragments also
5 retained a cleavage-ligation activity, similar to the "disintegration" activity originally described by Chow et al., Science 255: 723-726 (1992). Fusion of the lexA DBD to the 39-207 fragment resulted in retention of this "-3" cleavage activity. From the results in
10 Figure 2, we concluded that the N-terminal ZF-domain (1-40) is not essential for processing activity as assayed under these conditions. Lastly, the N-LIN and C-LIN proteins were assayed for processing and joining and displayed processing and joining activities similar
15 to wild type IN (data not shown).

The LexA DBD can influence integration site selection. Retroviral DNA integration into the host cell DNA is essentially random. Some models for IN structure-function suggest that a "non-specific DNA-
20 binding activity" could account for random selection of host integration sites. To determine whether the presence of a specific DNA binding domain (the LexA DBD) could influence integration site selection, IN or IN fusions were incubated with linearized target DNA
25 and a model viral DNA substrate. This substrate was a 16mer/18mer duplex with a "processed" end (the TT is removed, see Figure 2). A PCR based assay was used to score for integration of model viral DNA substrate into a plasmid target (see Material and Methods). The
30 target plasmid was pBR322 containing two tandem lexA operators inserted between the *Bam*HI and *Sal*I sites. Two PCR primers were used to detect integration events. One primer corresponds to a fixed site on the plasmid and the second primer corresponds to the viral sequence
35 to be inserted. The size of the resultant PCR fragments corresponds to the distance from a fixed site on the plasmid to the integration site. It should be

- 29 -

noted that this assay detects only insertion of what is equivalent to one viral DNA end, rather than the coordinated insertion event that takes place *in vivo*, involving the two ends of viral DNA.

5 In the experiment shown in Figure 3, the fixed PCR primer was ligated ca. 120 bp from the tandem *lexA* operators. The wildtype IN (lane 1) catalyzed integration into many sites and integration was not entirely random, as indicated by the varying
10 intensities of bands. If purified LexA repressor proteins was added prior to the addition of IN, the *lexA* operator region became protected from integration events, indicating that the repressor is bound to the operators (lane 2). A general reduction in integration
15 was also noted, which may be due to some nonspecific DNA binding of the LexA repressor protein. The patterns produced by N-LIN and C-LIN (lanes 3 and 5, respectively) were identical to each other, but differed from the pattern produced by wild type IN.
20 Integration events within the *lexA* operator region were quenched. These results indicate that the fusion proteins were binding to the *lexA* operators and thus blocking integration of unbound fusion proteins into this region. The use of a neighboring integration site
25 was tremendously enhanced in the case of both N-LIN and C-LIN (arrow). Significant enhancement of one other site closer to the primer was also noted (arrow). These results suggest that LexA DBD directs the N-LIN and C-LIN fusion proteins to the operator region and
30 that the bound fusion proteins direct integration into nearby sites. Preincubation with equimolar amounts of LexA repressor protein was not sufficient to block this activity, indicating that the fusion proteins are tightly bound (lanes 4 and 6). One alternative
35 explanation for the enhanced use of integration sites would be that the bound proteins distort the DNA helix in the vicinity of the operator and this may promote

- 30 -

selective utilization of sites in this region. However binding of the complete LexA repressor protein to the operator has no such effect on wild type IN (Figure 3, lane 2). Since tight binding to the operator requires
5 dimerization of the LexA DBD, we also conclude that the IN portion of the fusion provides a dimer interface.

Interdomain flexibility may be required for selection of neighboring integration sites. The results in Figure 3 suggested that LexA DBD-IN fusions
10 were bound at the operator region and that this binding promoted use of neighboring integration sites. Since two of the N-terminal intra-domain fusions, LIN 18-286 and LIN 39-286, were active for processing and joining (Figure 2), we used the PCR-based assay to access
15 their ability to target integration into sites adjacent to the operator. As controls, we assayed the corresponding deletion mutants, IN 18-286 and IN 39-286. The results shown in Figure 4 indicate that the N-terminal deletions did not abrogate the ability of
20 these proteins to direct integration into a heterologous target DNA (lanes 2 through 4). We therefore conclude that the complete ZF domain is not required for integration into a heterologous target DNA *in vitro*. However, the results indicate that, as
25 compared to wild type, the deletions result in a slight reduction in integration activity, as well subtle variations in integration site selection (compare lane 2 with lanes 3 and 4). The corresponding LIN 18-286 and LIN 39-286 proteins displayed quenching of
30 integration events in the operator region, indicating that these proteins are selectively bound at these operator sites (lanes 7 and 8). However, the neighboring integration site (arrow) is no longer preferred as in cases of N-LIN or C-LIN (lanes 5 and
35 6). The LIN 52-286 and LIN 39-207 proteins showed no activity under these conditions (lanes 9 and 10), as might be expected from the results in Figure 2. We

- 31 -

conclude that fusion of the LexA DBD within the ZF domain results in a highly active protein which can bind to *lexA* operators; however fusion at the precise N-terminus allows the selection of preferred sites neighboring the operator. One interpretation is that the precise N-terminal (and C-terminal) fusions allows sufficient flexibility for the IN domain to access neighboring sites, while intra-domain fusion does not.

Targeting of IN endonuclease activity. We used a second approach to assess the selective binding and activity of the LexA DBD-IN fusions at the *lexA* operator site. With Mn^{++} as a cofactor, ASV IN is able to nick and linearize supercoiled plasmids. This non-specific nicking seems to correspond to cleavage observed at the -3 site on the viral DNA substrates shown in Figure 2. The biological relevance of this activity is unknown, but it requires the conserved residues in the catalytic domain. The supercoiled substrate shown in Figure 5A is a pBR322 derivative lacking *lexA* operator sequences (lane 2). Two of the fusion proteins diagrammed in Figure 1, LIN 18-286 and LIN 39-286, were incubated with this plasmid in the presence of $MnCl_2$ and the products were analyzed on an agarose gel (Figure 5A, lanes 4 and 7, respectively). These fusion proteins, as well as wild type IN (lane 3) and the two non-fused catalytic domain fragments (lanes 5 and 6), all displayed similar levels of nicking activity as measured by production of form II (FII) and a small amount of linear form III DNA (FIII). These results confirm that the nicking activity maps to the ASV IN catalytic domain and is not affected considerably by various deletions and fusions. A similar experiment was carried out in Figure 5B, except that the supercoiled substrate plasmid, pBRBSLexAOP, contained tandem *lexA* operators. Strikingly, the efficiency of linearization is much greater with the four proteins that contain the LexA DBD (Figure 5B,

lanes 3, 4, 5 and 8 as compared to wild type IN or the non-fused central domain fragments (lanes 2, 6 and 7). The linear product (FIII) appears to be formed at the expense of supercoiled substrate (FI) indicating
5 concerted nicking. Although these assays are not highly quantitative, the selectivity for the operator is most pronounced when the IN 39-207 protein is compared to the corresponding LexA fusion protein, LIN 39-207 (Figure 5B, lanes 7 and 8, respectively).

10 The results shown in Figures 5A and 5B suggest that the enhanced linearization of the operator-containing plasmids was due to preferential binding of the *lexA*-IN fusion proteins to the operator region, followed by localized concerted nicking. A
15 linear substrate was used in order to map the preferred cleavage site in relation to a fixed site. The *lexA* operator-containing substrate was linearized with *Pst*I, purified and then incubated with unfused IN or LIN 18-286. The results, shown in Figure 5C, demonstrate that
20 the LexA-IN fusion was able to preferentially cleave at or near the *lexA* operator, as indicated by generation of two discrete fragments of ca. 3400bp and 1300bp. These fragments migrated with the two marker fragments generated by cleavage with *Xho*I, which cleaves at the
25 operator sites. All other LexA-IN fusions tested showed a similar profile on *Pst*I-linearized substrates (data not shown). The bands produced by LIN 18-286 were somewhat heterogeneous, indicating that the ends might be frayed (Figure 5C, lane 5). Fractionation of
30 labelled DNAs on higher resolution gels confirmed that the termini produced by LIN 18-186 corresponded to many sites within, and flanking, the *lexA* operator region (data not shown).

35 As can be seen in Figure 5C, lane 4, wild type IN does not produce any major uniform fragments from the linear DNA substrate, indicating that double strand breaks occur less frequently and less

- 33 -

selectively. Interesting, when gels similar to that shown in Figure 5C were probed after Southern blotting, the results indicated that the major site of double strand breaks produced by unfused IN also produced by unfused IN also corresponded to the *lexA* operator region. We believe that the tandem array of palindromic operators may present a highly structured region of DNA which may be generally sensitive to nucleases and thus may enhance the detection of double strand breaks by both the fused and unfused IN proteins.

From these experiments, we conclude that the Mn-dependent nicking activity of the ASV IN catalytic domain can be directed to *lexA* operator sites by fusion with the LexA DBD and this results in site-specific double stranded breaks.

The C-LIN protein is functional *in vivo*. One object of this invention is to influence, or re-direct retroviral DNA integration using a modified IN protein. Since the N-terminus of IN is fused to the RT in the *gag-pol* precursor in all retroviruses, it would be difficult to engineer a DBD (e.g. N-LIN) at this site in the viral genome. For example, a new viral protease (PR) site would have to be engineered in order to release the IN fusion from the *gag-pol* precursor. Also, in the case of ASV, IN exists as a domain of the RT β -chain, as well as a free peptide; thus, the heterologous DBD would likely interrupt folding of the RT β -chain. We therefore constructed an ASV DNA clone which encodes C-LIN, such that the DBD was tethered to the C-terminus of IN as well as to the C-terminus of the RT β -chain. This required re-engineering of the 3'-end of the *pol* gene in a manner which would not disturb *cis*-acting signals or overlapping coding regions. The same strategy was used to generate the bacterial expression construct and the relevant fragment was simply shifted to the viral DNA clone.

- 34 -

Normally, the IN coding region partially overlaps with the env coding region (Figure 6). The overlapping portion encodes a C-terminal ca. 4kDa peptide that is removed by the viral protease (PR) during virion morphogenesis and this peptide was shown to be nonessential (Katz & Skalka, 1988, *supra*). We therefore replaced the coding sequences for this peptide with the coding sequence for the LexA DBD. The cleavage site for PR should be destroyed by the fusion step. In order to preserve the intronic portion of the env splice acceptor site (which also overlaps with the IN coding region) we used a starting clone pLD6IS1 (Katz & Skalka, 1988, *supra*) which contains a noncoding spacer between env and pol (figure 6, denoted nc). The spacer also contains a cis-acting suppressor mutation which was selected *in vivo* to maintain RNA splicing regulation.

DNA transfection of susceptible chicken cells with the C-LIN viral construct resulted in the appearance of infectious virus (Figure 7A). There was significant delay as compared to wild type, indicating that the alterations produced a replication defect. The delay was not due to use of the pLD6IS1 parent, since this virus replicates at a similar rate as wild type. These results indicated that viruses containing the additional IN domain have some replicative capacity; however the delay, followed by rapid appearance of infectious virus (between days 15 and 18) suggested the possibility of a genetic change that restored full replicative capacity. In comparison, replacement of the conserved carboxylates residues of the catalytic domain (Figure 1) results in a complete block in ASV replication when assayed under similar conditions.

Western blot analysis (Figure 8) using both anti-IN and anti-LexA repressor antibodies demonstrated that viruses from pLD6IS1 C-LIN-transfected cultures

- 35 -

contained a mixture of C-LIN (ca. 42kDa) and IN-like proteins (32 KDa). At day 30 post transfection, the C-LIN to IN ratio was approximately 1 to 5 (Figure 8A). As predicted, the LexA DBD is also detected on the β -chain of RT (Figure 8B). In similar western blots from virus collected at earlier times (e.g., days 16 and 17) the C-LIN to IN ratio was approximately to one-to-one (data not shown), suggesting a gradual loss of the LexA DBD. The free LexA DBD could not be detected in viral particles (data not shown) suggesting that the loss of this domain was the result of a genetic change, rather than proteolytic cleavage. To confirm the apparent genetic instability of the C-LIN virus, culture supernatant were collected at day 25 from the transfections shown in Figure 7A, normalized by reverse transcriptase activity and then re-applied to fresh cells. As expected, virus collected from the C-LIN cultures now appeared at a similar rate to wild type. We note that the band corresponding to IN in the C-LIN-transfected cultures does not appear as the characteristic "doublet" of wild type IN. This observation suggest that the restored IN is not simply wild type and further analyses are under way. From these experiments we concluded that the C-LIN protein is produced *in vivo* and is assembled into virus particles. Although there is genetic selection against viruses that encode this domain, the C-LIN protein is likely functional *in vivo* (see Discussion) and is relatively stable.

DISCUSSION

The selection of retroviral integration sites is essentially random within host cell DNA, when catalyzed by a wildtype integrase. The evidence presented here demonstrates that IN can be augmented such that it is directed to a specified DNA sequence. This approach allows the study and use of IN molecules

- 36 -

bound at a particular site on the DNA.

We have shown that fusion of the LexA DBD to either the N- or C-termini of ASV IN strongly influences integration site selection *in vitro*. The results are consistent with the binding of these fusion proteins to *lexA* operator sequences followed by enhanced the use of an adjacent integration site. The preferred integration site is located approximately one turn of the DNA helix from the *lexA* operator sites.

Fusion of the LexA repressor to the precise IN termini appears to be important for preferential integration into neighboring sites. For example, LIN 18-286 and LIN 39-286 are active for integration and are also able to bind to operators (Figure 4); however, these fusions do not preferentially select the neighboring integration site used by N-LIN (and C-LIN). One interpretation of these results is that there must be sufficient flexibility between the two fusion partners such that the neighboring integration site can be accessed. Interestingly, the intra-domain fusions LIN 18-286, LIN 39-286 and LIN 52-286 were able to selectively introduce double strand breaks within or adjacent to the operator region, indicating that the juxtaposition of domains is not critical for this activity (Figure 5). Alternatively, the double-strand break assay may be inherently less quantitative and perhaps more sensitive.

The N-LIN and C-LIN fusions both selected the same preferred integration sites adjacent to the operators. This result suggests that these two fusions may be similarly positioned on the DNA, consistent with the notion that N- and C-termini are adjacent in the native IN structure.

The observation that all of the fusions proteins can be efficiently targeted to the operator region suggests that the IN domain provides a dimer interface. The LexA repressor normally binds to its

- 37 -

cognate operator as a dimer, with the DBDs from each monomer contacting a "half-site" of the operator sequence (Figure 1). The LexA repressor DBD (1-87) has been used extensively as a fusion partner to detect activation domains of transcription factors. To be efficient, the system requires that a multimerization domain be present. The positioning of the LexA DBD in relation to the dimerization domain is also important: the two DBDs in the dimer must be able to contact both halves of the operator simultaneously for high affinity binding. ASV IN functions as a multimer and biochemical mapping studies have indicated that self-association functions are contributed by both the catalytic domain and the C-terminal domain. Genetic analysis has also indicated that the catalytic domain of HIV IN contains a self-association function. The results presented here are consistent with the catalytic domain providing a dimer interface.

We also observed that fusion of the LexA DBD to positions 18 and 39 of ASV IN (LIN 18-286, LIN 39-286) resulted in retention of processing and joining activity, while fusion at position 52 (LIN 52-286) resulted in a severe reduction in activity (Figures 2 and 4). These fusions interrupt the conserved ZF domain. Although the isolated ZF domain does not bind to DNA, it has been implicated in DNA binding within the context of the whole IN protein. To determine if the LexA DBD might be complementing ZF domain function, we analyzed the corresponding deletion mutants (IN 18-286, IN 39-286). We find that these mutant proteins are also active, although their activity may be slightly reduced as compared to their fusion counterparts (Figure 4). Thus, the ZF domain is not essential for processing or joining to a heterologous target DNA *in vitro*. Bushman and Wang (J. Virol. 68: 2215-2223, 1994) have reported similar results, except that the fusion of short heterologous peptides was

- 38 -

required to complement the ZF deletion. We showed previously that the ASV ZF domain was not sufficient for DNA binding, although we did detect modest effects of single amino acid substitutions of either histidine 9 (H9) or histidine 13 (H13) residues (see Figure 1) in the presence of $MgCl_2$. Here we show that the various ASV ZF deletion and fusion constructs are capable of catalyzing the insertion of model viral DNA ends into a heterologous target DNA in the presence of $MgCl_2$. Mn^{++} is the preferred metal co-factor for ASV In *in vitro* and thus the use of the more biologically relevant, but less active, Mg^{++} co-factor (Figures 3 and 4) provides a more stringent screen for the effects of these mutations. Although the ZF domain is not required *in vitro*, its conservation suggests that it does indeed have an important function. Substitution of ASV H9 or H13 produces a severe replication defect *in vivo* (not shown), which agrees with similar experiments in the HIV-1 system.

We provide evidence that all of the IN-LexA DBD fusions described here have varying degrees of selectivity for operator sequences. Although the relative binding of native IN versus fused IN was not directly measured, the results shown in Figure 5 indicate an approximate 5-10 fold selectivity for introducing double strand breaks at or near the operator region. How might the LIN fusion proteins be arranged on the operator region to promote cleavage of both strands? Under limited nicking conditions, we observe many breaks focused within the operator region, but emanating to more distant sites. This suggests, that IN or IN segments are able to make DNA contacts at some distance from the operator. The contact could be through aggregation of LIN molecules along the DNA or looping in of neighboring DNA sequences through binding to the catalytic domain. Although these possibilities cannot be distinguished from the experiments performed

- 39 -

thus far, we generally believe that the enhancement of double strand breaks is the result of a high local concentration of LIN molecules at the operator region.

The fusion proteins described here enhance
5 integration at a specific site, but integration events are not dependent on the operator sequences. Achieving absolute operator-dependent integration may require optimizing the arrangement of the IN dimer interface and the LexA DBD such that the cooperative interactions
10 that occur between the native LexA repressor protein dimer and the operator can be fully reproduced. Greater selectivity might also be achieved by inactivating the IN domain that is normally responsible for binding to random host DNA. This non-specific DNA
15 binding activity may map to the C-terminus of IN (Khan et al., Nucl. Acids Res. 19: 851-860, 1990) inasmuch as removal of this entire domain results in increased selectivity in the double strand break assay shown in Figure 5 (LIN 39-207). Perhaps the arrangement of *lexA*
20 operator sequences could also be optimized. In the experiments shown in Figures 4 and 5, we used two tandem operators that are in phase along the helix (Figure 1). We speculated that this arrangement might promote higher order interactions between fusion dimers
25 bound at each operator. It is possible that higher order IN complexes (e.g. tetrameres) are the active form for the joining reaction of the viral ends to target sequences and this tandem operator arrangement might increase IN activity by promoting such complexes.
30 Although this hypothesis has not been systematically tested, we have found that single operators or tandem out-of-phase operators (such as used in Figure 5) are sufficient for binding and double strand break activity, but not for the efficient, selective joining
35 activities of C-LIN and N-LIN displayed in Figures 3 and 4.

The fusion protein strategy we have described

- 40 -

has also shown potential for targeting or enhancing retroviral integration *in vivo*. The C-LIN protein is highly active *in vitro*, is able to bind to *lexA* operators and promotes integration into nearby regions.

5 We have also shown that it can be assembled into viral particles (Figure 8), and our experiments indicate that the C-LIN fusion is active *in vivo*. Under our standard transfection conditions (Figure 7), RT activity could not be detected unless multiple rounds of infection

10 have occurred. For example, DNA transfection with an IN catalytic site mutant did not produce sufficient RT activity for detection (data not shown) because there was no significant amplification by cell-to-cell spread. Under our standard conditions, catalytic site

15 IN mutants do not revert, presumably because this would require low-level replication. The results in Figure 7 suggested that pLD6IS1 C-LIN virus was partially defective due to the presence of the extra IN domain, but could replicate sufficiently such that stabilizing

20 mutations arose. Results of western blot analysis at early and late times support this interpretation. We conclude that the C-LIN protein is likely functional *in vivo*. We also considered the possibility that C-LIN molecules undergo proteolytic cleavage within the viral

25 particle such that the LexA DBD is released and that the resulting nonfused IN is the biologically active form. However, we have not detected the expected ca.87 amino acid peptide in viral particles.

In summary, our results demonstrate the

30 potential for augmentation of IN activity *in vitro* and *in vivo*. It can be postulated that an additional IN domain could also be used to target the retroviral pre-integration complex to protein components as well as DNA targets. The targeting and/or enhancement of

35 retroviral integration should be extremely useful for basic research, to probe the interrelationship between various genes in complex gene expression pathways, as

- 41 -

well as for gene therapy.

5 The present invention is not limited to the
embodiments described above, but is capable of
variation and modification without departure from the
scope of the appended claims.

- 42 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Katz, Richard A.
Skalka, Anna Marie
- (ii) TITLE OF INVENTION: Chimeric Enzyme for Promoting Targeted
Integration of Foreign DNA into a Host Genome
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Dann, Dorfman, Herrell & Skillman
 - (B) STREET: 1601 Market Street, Suite 720
 - (C) CITY: Philadelphia
 - (D) STATE: PA
 - (E) COUNTRY: USA
 - (F) ZIP: 19103
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE: 09-MAY-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Reed, Janet E.
 - (B) REGISTRATION NUMBER: 36,252
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (215) 563-4100
 - (B) TELEFAX: (215) 563-4044

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 63 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGGGTCGACA TTACTGTATA TATATACAGC ATAACTGTAT ATATATACAG TATAGGATCC

60

GGG

63

- 43 -

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ser	Pro	Leu	Phe	Ala	Lys	Ala	Leu	Thr	Ala	Arg
1				5					10	

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGCGCGAGCC CGTTATTCGC TAAAGCGTTA ACGGCCAGG

39

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Val	Ala	Ala	Gly	Glu	Pro	Ala
1				5		

- 44 -

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCGCGCTTAA GCTGGTTCAC CGGCAGCCAC

30

- 45 -

What is claimed is:

1. A chimeric enzyme comprising a DNA binding moiety and an integrase moiety derivable from a retroelement, said enzyme being capable of binding to a target DNA molecule having a characteristic determinant recognized by the DNA binding moiety, said enzyme having at least one activity characteristic of a retroelement integrase.
2. The chimeric enzyme of claim 1, wherein said retroelement is a retrovirus.
3. The chimeric enzyme of claim 2, wherein said retrovirus is selected from the group consisting of ASV, HIV, HFV, Mo-MLV, VISNA and FIV.
4. The chimeric enzyme of claim 1, wherein said retroelement is Ty-1.
5. The chimeric enzyme of claim 3, wherein said integrase moiety is ASV integrase and said DNA binding moiety is obtained from a Lex A DNA binding protein.
6. The chimeric enzyme of claim 1, wherein said DNA binding moiety is appended to said integrase moiety at one terminus of said integrase moiety.
7. The chimeric enzyme of claim 6, wherein said DNA binding moiety is appended to said integrase moiety at the amino terminus of said integrase moiety.
8. The chimeric enzyme of claim 6, wherein said DNA binding moiety is appended to said integrase moiety at the carboxyl terminus of said integrase moiety.

- 46 -

9. The chimeric enzyme of claim 1, wherein said integrase moiety is truncated from its amino terminus so as to remove part or all of its ZF domain, and said DNA binding moiety is appended to said integrase moiety at said truncated amino terminus.

10. The chimeric enzyme of claim 1, wherein said DNA binding domain is derivable from a DNA binding protein selected from the group consisting of helix-turn-helix proteins and b/hlh/z proteins.

11. The chimeric enzyme of claim 1, wherein said at least one activity of said retroelement integrase is selected from the group consisting of:

- (a) processing of retroelement DNA termini;
- (b) nicking within double stranded DNA;
- (c) integrating a DNA molecule having processed retroelement termini into DNA molecule; and
- (d) a combination of (a), (b) or (c).

12. The chimeric enzyme of claim 6, wherein said at least one activity of said retroelement integrase is integrating a DNA molecule having processed retroelement termini into said target DNA molecule, and said integrating activity is directed to a site on said target DNA adjacent to said characteristic determinant recognized by said DNA binding moiety.

13. A nucleic acid molecule having a sequence that encodes the chimeric enzyme of claim 1.

14. A nucleic acid molecule having a sequence that encodes a chimeric enzyme comprising a DNA binding moiety and an integrase moiety derivable from a retroelement, said enzyme being capable of binding to a target DNA molecule having a characteristic determinant

- 47 -

recognized by the DNA binding moiety, said enzyme having
at least one activity characteristic of a retroelement
integrase, said nucleic acid molecule comprising a DNA
binding moiety-encoding segment operably linked to an
5 integrase-encoding segment derivable from a retroelement.

15. The nucleic acid molecule of claim 14,
wherein said retroelement is a retrovirus.

10 16. The nucleic acid molecule of claim 14,
wherein said retrovirus is selected from the group
consisting of ASV, HIV, HFV, Mo-MLV, VISNA and FIV.

15 17. The nucleic acid of claim 14, wherein said
retroelement is Ty-1.

18. The nucleic acid molecule of claim 16,
wherein said integrase-encoding segment is obtained from
an ASV genome and said DNA binding moiety-encoding
20 segment is obtained from a gene that encodes a Lex A DNA
binding protein.

19. The nucleic acid molecule of claim 14,
wherein said integrase moiety-encoding segment and said
25 DNA binding moiety-encoding segment are operably linked
such that expression of said nucleic acid molecule
produces said chimeric enzyme in which said DNA binding
moiety is appended to said integrase moiety at one
terminus of said integrase moiety.

30 20. The nucleic acid molecule of claim 19,
wherein said one terminus of said integrase moiety is the
amino terminus.

35 21. The nucleic acid molecule of claim 19,
wherein said one terminus of said integrase moiety is the
carboxyl terminus.

- 48 -

22. The nucleic acid of claim 14, which upon expression produces a chimeric enzyme in which said integrase moiety is truncated from its amino terminus so as to remove part or all of its ZF domain, and said DNA
5 binding moiety is appended to said integrase moiety at said truncated amino terminus.

23. The nucleic acid molecule of claim 14, wherein said DNA binding domain-encoding segment is
10 obtained from a gene encoding a DNA binding protein selected from the group consisting of helix-turn-helix proteins and b/hlh/z proteins.

24. A vector comprising the nucleic acid
15 molecule of claim 14.

25. The vector of claim 24, which is a retroviral vector.

20 26. A replication-competent retroviral vector comprising the nucleic acid molecule of claim 21.

27. The vector of claim 24, which is an expression vector selected from the group consisting of a
25 procaryotic cellular expression vector, a eucaryotic cellular expression vector and a cell-free expression vector.

28. A chimeric enzyme produce by expression of
30 the nucleic acid molecule of claim 14.



BamHI

Sail

GGATCCTATACTGTATATATACAGTTATGCTGTATATATATACAGTAATGTCGAC
CCTAGGATATGACATATATATATGTCAATACGACATATATATATGTCATTACAGCTG

operator 1 operator 2

FIG. 45

Sa/I

operator 2

FIG. 1B

SUBSTITUTE SHEET (RULE 26)




FIG. 2A




FIG. 2B

SUBSTITUTE SHEET (RULE 26)




FIG. 3

5 / 9




FIG. 4

SUBSTITUTE SHEET (RULE 26)

6 / 9




FIG. 5A




FIG. 5B





FIG. 5C



...SER PRO LEU PHE ALA LYS ALA LEU THR ALA ARG...
 5'CGCGCG AGG CCG TTA TTC GCT AAA GCG TTA ACG GCC AGG 3'
 Ban II

...VAL ALA ALA GLY GLU PRO ALA STOP
 3'CAC CGA CCG CCA CTT GGT CGA ATTGCGCG 5'
 Afl II

IN LexA DBD LexA DBD

FIG. 6




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B

1 2 3
α-Lex A repressor

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/06569

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 9/00; C07H 19/00, 21/00; C07K 1/00, 14/00, 17/00

US CL : 536/22.1; 530/350; 435/183

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/22.1; 530/350; 435/183

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
USPAFULL, WPIDS, MEDLINE, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PAHL et al. Characterization of the human spuma retrovirus integrase by site-directed mutagenesis, by complementation analysis, and by swapping the zinc finger domain of HIV-1. The Journal of Biological Chemistry. 17 February 1995, Vol. 270, No. 7, pages 2957-2966, see the entire document.	13-16, 19-20, 24-25, and 27
X	TERRY et al. Properties of avian sacroma-leukosis virus pp32-related pol-endonucleases produced in Escherichia coli. Journal of Virology. July 1988, Vol. 62, No. 7, pages 2358-2365, see the entire document.	13-16, 19, 24-25, and 27

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 JUNE 1996

Date of mailing of the international search report

17 5 JUL 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ETHEAN WHISENANT

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/06569

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DEVINE et al. Efficient integration of artificial transposons into plasmid targets in vitro: a useful tool for DNA mapping, sequencing and genetic analysis. Nucleic Acids Research. September 1994, Vol. 22, No. 18, pages 3765-3772, see the entire document.	4, 17
Y	KATZMAN et al. The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration. Journal of Virology. December 1989, Vol. 63, No. 12, pages 5319-5327, see the entire document.	3, 18
Y	HORII et al. Nucleotide sequence of the lexA gene of E. coli. Cell. March 1981, Vol. 23, pages 689-697, see the entire document.	3, 18
Y	WOENER et al. Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Research. July 1993, Vol. 21, No. 15, pages 3507-3511, see the entire document.	8, 21, 26
Y	BURLEY et al. DNA-binding motifs from eukaryotic transcription factors. Current Opinions in Structural Biology. April 1994, Vol.4, pages 3-11, see the entire document.	10, 23
Y,P	KATZMAN et al. Mapping domains of retroviral integrase responsible for viral DNA specificity and target site selection by analysis of chimeras between Human immunodeficiency virus Type 1 and Visna virus integrases. Journal of Virology. September 1995, Vol. 69, No. 9, pages 5687-5696, see the entire document.	1-28
Y,P	GOULAOUIC et al. Directed integration of viral mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. Journal of Virology. January 1996, Vol. 70, No. 1, pages 37-46, see the entire document.	1-28

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/06569

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/06569

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-12 and 28, drawn to a chimeric enzyme.

Group II, claim(s) 13-27, drawn to nucleic acid molecule which encodes the chimeric enzyme.

The inventions listed as Groups I and II do not relate to a single inventive concept because, multiple products are claimed. While these products are linked by a special technical feature they lack unity of invention as defined in 37 CFR 1.475. The Claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

